# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...
-SEC Filing
Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological...
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect...
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...
- SEC Filing
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe ...
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $...